-
Mashup Score: 2
We summarize key results from the phase II GMMG-CONCEPT trial investigating transplant-eligible and non-transplant-eligible patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone, followed by triplet maintenance.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
We summarize key results from the phase II GMMG-CONCEPT trial investigating transplant-eligible and non-transplant-eligible patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone, followed by triplet maintenance.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Outcomes of patients with NDMM, transplanted with Vel-Mel or Mel200 conditioning regimens - 3 month(s) ago
We summarize a retrospective analysis by Beksac et al. investigating the outcomes of patients with newly diagnosed multiple myeloma, transplanted with Vel-Mel or Mel200 conditioning regimens.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
What are the clinical outcomes of Isa-KRd treatment in high-risk newly diagnosed #multiplemyeloma? Read our summary of the results from the phase II GMMG-CONCEPT trial to learn more! https://t.co/N0C9B08AM5 #MMsm #myeloma #MedicalEducation https://t.co/WbsGI1Q9QP